The absence of institutional selling and the magnitude of passive buying suggest strong underlying demand. Traders should monitor for follow-on buying, upcoming clinical trial data, or potential inclusion in broader index rebalancing. Consider this a bullish signal ahead of potential catalysts.
CLDX drugs
CLDX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $30.00entry
- T+1 · 9mo ago −3.53%α −2.62% · $28.94
- T+5 · 8mo ago +2.43%α +3.64% · $30.73
- T+20 · 8mo ago −1.73%α +6.20% · $29.48
- T+60 · 6mo ago +2.83%α −6.49% · $30.85
How similar events traded
Executive Summary
Three major passive institutional investors, Morgan Stanley, Wells Fargo, and UBS, significantly increased their positions in Celldex Therapeutics (CLDX) during 2024-Q4, collectively adding $25.1 million in new holdings. All three funds doubled their exposure, indicating strong institutional accumulation despite no active sellers. This coordinated buying suggests growing confidence in CLDX's pipeline or valuation at current levels.
Key Financial Metrics
Institutional Positions
Net institutional flow: $25.1M
▲ Buyers (3)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Morgan Stanley | DOUBLED | +208.4% | $34.0M | $19.2M |
| Wells Fargo | DOUBLED | +352.4% | $2.6M | $1.8M |
| UBS | DOUBLED | +134% | $9.9M | $4.2M |
Key Facts
- Morgan Stanley increased CLDX holdings by $19.2M (from $14.8M to $34.0M), doubling position size.
- Wells Fargo added $1.8M (from $762K to $2.6M), increasing shares by 352.4%.
- UBS boosted position by $4.2M (from $5.7M to $9.9M), up 134% in shares.
- No institutional selling observed in this quarter, net directional flow is strongly positive.
- Total institutional buying: $25.1M net new capital deployed across three mega-passive firms.
Financial Impact
Three institutions accumulated $25.1M in net new positions during 2024-Q4, increasing total passive ownership value from $21.3M to $46.4M.
Risk Factors
- All buyers are passive managers, suggesting the move may reflect index rebalancing rather than active conviction.
- Lack of active fund participation limits the strength of the bullish signal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-CLDX-2024-Q4 |
Track record
21 reports on CLDX
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +19.96% at T+20 after the Jun 14, 2026 report. 3 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $28.97 settles Feb 12
- Nov 5, 202611d ago S-3ASR Neutral 3/10 Entry $29.87 settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $29.87 settles Feb 4
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $29.71 settles Feb 1
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $30.43 settles Jan 4
- Sep 22, 20267w ago Institutional Cluster Bullish 4/10 Entry $33.51 settles Dec 16
- Sep 22, 20267w ago 8-K Bullish 7/10 Entry $33.51 settles Dec 16
- Sep 22, 20267w ago Press Release Bullish 7/10 Entry $33.51 settles Dec 16
- Jun 14, 202622w ago Press Release Bearish 6/10 Entry $32.12 to $38.10 ▼ −18.62% −18.22% vs SPY
- Jun 14, 202622w ago Press Release Bullish 7/10 Entry $32.12 to $38.10 ▲ +18.62% +18.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers